Published in Cancer Cell on May 23, 2013
Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card (COMETETACTIC) | NCT02672020
Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature (2016) 2.92
The Emerging Hallmarks of Cancer Metabolism. Cell Metab (2016) 2.32
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Oncometabolites: linking altered metabolism with cancer. J Clin Invest (2013) 1.78
Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab (2014) 1.74
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet (2013) 1.53
Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer (2014) 1.33
Defects in mitochondrial metabolism and cancer. Cancer Metab (2014) 1.24
Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol (2015) 1.22
Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer (2014) 1.17
TET proteins and the control of cytosine demethylation in cancer. Genome Med (2015) 1.13
Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev (2014) 1.07
Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun (2015) 1.06
Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol (2015) 1.03
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. J Biol Chem (2015) 0.99
Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab (2014) 0.97
Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations. Genet Med (2014) 0.97
A new specific succinate-glutamate metabolomic hallmark in SDHx-related paragangliomas. PLoS One (2013) 0.96
Metabolic control of epigenetics in cancer. Nat Rev Cancer (2016) 0.94
Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors. Oncotarget (2015) 0.93
Metabolic mechanisms of epigenetic regulation. ACS Chem Biol (2013) 0.92
Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat Commun (2015) 0.92
A systems approach to predict oncometabolites via context-specific genome-scale metabolic networks. PLoS Comput Biol (2014) 0.90
Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2014) 0.89
Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer (2014) 0.88
Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging (2015) 0.87
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun (2015) 0.87
Metabolic regulation of histone post-translational modifications. ACS Chem Biol (2015) 0.87
Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer Metab (2014) 0.87
Metabolic control of methylation and acetylation. Curr Opin Chem Biol (2015) 0.86
Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. Cell Cycle (2014) 0.86
Epigenetics and cancer metabolism. Cancer Lett (2013) 0.86
Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. Neoplasia (2015) 0.86
Oncometabolites: tailoring our genes. FEBS J (2015) 0.85
Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. EMBO J (2017) 0.85
Metabolism and Epigenetics. Annu Rev Cell Dev Biol (2015) 0.83
Oncometabolic Nuclear Reprogramming of Cancer Stemness. Stem Cell Reports (2016) 0.83
Succinate: a new epigenetic hacker. Cancer Cell (2013) 0.83
Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene (2015) 0.83
SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity. Mol Genet Genomic Med (2017) 0.82
Flux balance analysis predicts essential genes in clear cell renal cell carcinoma metabolism. Sci Rep (2015) 0.82
Cancer Metabolism: Fueling More than Just Growth. Mol Cells (2016) 0.82
Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis (2014) 0.82
The role of 5-hydroxymethylcytosine in human cancer. Cell Tissue Res (2014) 0.81
The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas. Epigenetics (2013) 0.81
Heme exporter FLVCR is required for T cell development and peripheral survival. J Immunol (2015) 0.81
Metformin targets histone acetylation in cancer-prone epithelial cells. Cell Cycle (2016) 0.81
SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. J Natl Cancer Inst (2016) 0.81
Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer (2016) 0.80
Oxygen concentration controls epigenetic effects in models of familial paraganglioma. PLoS One (2015) 0.80
Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. Eur J Hum Genet (2015) 0.80
The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations. Endocrine (2014) 0.80
Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res (2015) 0.80
Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer. Front Cell Dev Biol (2017) 0.80
Mitochondrial Deficiencies in the Predisposition to Paraganglioma. Metabolites (2017) 0.79
Establishment of a DNA methylation marker to evaluate cancer cell fraction in gastric cancer. Gastric Cancer (2015) 0.79
Is glioblastoma an epigenetic malignancy? Cancers (Basel) (2013) 0.79
Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas. PLoS One (2015) 0.79
Clinical significance of T cell metabolic reprogramming in cancer. Clin Transl Med (2016) 0.79
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell (2017) 0.79
Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies. Fam Cancer (2014) 0.78
Genetically modeled mice with mutations in mitochondrial metabolic enzymes for the study of cancer. Front Oncol (2014) 0.78
Pheochromocytoma: The First Metabolic Endocrine Cancer. Clin Cancer Res (2016) 0.78
Metabolism: Epigenetic links to the web of Krebs. Nat Rev Cancer (2013) 0.78
Oncometabolites: Unconventional triggers of oncogenic signalling cascades. Free Radic Biol Med (2016) 0.78
Tracking the Correlation Between CpG Island Methylator Phenotype and Other Molecular Features and Clinicopathological Features in Human Colorectal Cancers: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol (2016) 0.78
Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. Oncotarget (2015) 0.77
Role of mitochondrial dysfunction in cancer progression. Exp Biol Med (Maywood) (2016) 0.77
(18)F-DOPA: the versatile radiopharmaceutical. Eur J Nucl Med Mol Imaging (2016) 0.77
Instability of succinate dehydrogenase in SDHD polymorphism connects reactive oxygen species production to nuclear and mitochondrial genomic mutations in yeast. Antioxid Redox Signal (2015) 0.76
Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov (2017) 0.76
Mitochondrial metabolic remodeling in response to genetic and environmental perturbations. Wiley Interdiscip Rev Syst Biol Med (2016) 0.76
Metabolic control of the epigenome in systemic Lupus erythematosus. Autoimmunity (2013) 0.76
Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use. Arch Immunol Ther Exp (Warsz) (2016) 0.76
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med (2016) 0.76
(18)F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. Eur J Nucl Med Mol Imaging (2016) 0.76
Redox-Related Epigenetic Mechanisms in Glioblastoma: Nuclear Factor (Erythroid-Derived 2)-Like 2, Cobalamin, and Dopamine Receptor Subtype 4. Front Oncol (2017) 0.75
Metabolic interactions with cancer epigenetics. Mol Aspects Med (2016) 0.75
Complex role of HIF in cancer: the known, the unknown, and the unexpected. Hypoxia (Auckl) (2014) 0.75
Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors. Front Oncol (2017) 0.75
Aberrant epigenetic regulation in clear cell sarcoma of the kidney featuring distinct DNA hypermethylation and EZH2 overexpression. Oncotarget (2016) 0.75
Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics. Int J Endocrinol (2015) 0.75
Global DNA Methylation Analysis Identifies Two Discrete clusters of Pheochromocytoma with Distinct Genomic and Genetic Alterations. Sci Rep (2017) 0.75
Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites? PLoS One (2015) 0.75
Undercover: gene control by metabolites and metabolic enzymes. Genes Dev (2016) 0.75
HRAS mutation prevalence and associated expression patterns in pheochromocytoma. Genes Chromosomes Cancer (2016) 0.75
SDHB deficiency promotes TGFβ-mediated invasion and metastasis of colorectal cancer through transcriptional repression complex SNAIL1-SMAD3/4. Transl Oncol (2016) 0.75
The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity. Cancer Metab (2017) 0.75
Fumarate hydratase is a critical metabolic regulator of hematopoietic stem cell functions. J Exp Med (2017) 0.75
Pheochromocytoma in a Twelve-Year-Old Girl with SDHB-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome. Case Rep Genet (2014) 0.75
Mitochondrial control through nutritionally regulated global histone H3 lysine-4 demethylation. Sci Rep (2016) 0.75
The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1α in cancer cells, induces cell death, and reduces tumor xenograft growth. Hypoxia (Auckl) (2016) 0.75
Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma. PLoS One (2015) 0.75
Radiopharmaceuticals in paraganglioma imaging: too many members on board? Eur J Nucl Med Mol Imaging (2015) 0.75
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism. Hypoxia (Auckl) (2014) 0.75
Four generations of SDHB-related disease: complexities in management. Fam Cancer (2016) 0.75
Modeling dioxygenase enzyme kinetics in familial paraganglioma. Biol Open (2015) 0.75
Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma. Pediatr Blood Cancer (2016) 0.75
IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. Clin Sarcoma Res (2017) 0.75
Sdhd ablation promotes thyroid tumorigenesis by inducing a stem-like phenotype. Endocr Relat Cancer (2017) 0.75
Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet (2004) 4.11
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82
Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab (2007) 3.25
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19
SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet (2010) 3.07
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet (2006) 2.86
Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet (2013) 2.83
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.72
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med (2013) 2.66
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet (2007) 2.64
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension (2012) 2.31
Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol (2003) 2.30
Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res (2003) 2.29
Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol (2011) 2.23
The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab (2009) 2.22
Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension (2009) 2.20
Fibromuscular dysplasia. Orphanet J Rare Dis (2007) 2.18
Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. Hum Mol Genet (2004) 2.15
Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab (2007) 2.06
Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA. Science (2011) 2.04
SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet (2008) 2.00
S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab (2007) 1.92
Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res (2005) 1.92
Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab (2004) 1.91
Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS (2003) 1.88
Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS (2006) 1.85
Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab (2002) 1.84
Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. Hum Mutat (2010) 1.81
ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med (2013) 1.79
The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One (2009) 1.75
Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab (2005) 1.75
Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens (2008) 1.75
Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol (2009) 1.73
Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. Cancer Res (2006) 1.72
Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood (2004) 1.71
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell (2008) 1.70
Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab (2006) 1.67
A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab (2012) 1.64
Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer (2007) 1.63
Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant (2004) 1.61
Oncometabolites-driven tumorigenesis: From genetics to targeted therapy. Int J Cancer (2014) 1.60
Evidence for carotid and radial artery wall subclinical lesions in renal fibromuscular dysplasia. J Hypertens (2003) 1.59
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood (2004) 1.59
Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab (2002) 1.59
Muscle-specific loss of apoptosis-inducing factor leads to mitochondrial dysfunction, skeletal muscle atrophy, and dilated cardiomyopathy. Mol Cell Biol (2005) 1.58
Cytochrome oxidase in health and disease. Gene (2002) 1.57
Spectrum of mutations in Gitelman syndrome. J Am Soc Nephrol (2011) 1.57
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab (2007) 1.53
Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med (2007) 1.52
KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension (2011) 1.51
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol (2012) 1.51
Prophenoloxidase activation is not required for survival to microbial infections in Drosophila. EMBO Rep (2006) 1.49
Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer (2009) 1.48
18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. Eur J Endocrinol (2004) 1.47
Cytochrome c oxidase subassemblies in fibroblast cultures from patients carrying mutations in COX10, SCO1, or SURF1. J Biol Chem (2003) 1.45
SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab (2011) 1.42
Pheochromocytomas and secreting paragangliomas. Orphanet J Rare Dis (2006) 1.41
Respiratory chain deficiency in a female with Aicardi-Goutières syndrome. Dev Med Child Neurol (2006) 1.41
Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension (2013) 1.41
Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int (2011) 1.39
Protein kinase A effects of an expressed PRKAR1A mutation associated with aggressive tumors. Cancer Res (2008) 1.39
Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet (2010) 1.38
Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet (2011) 1.38
The human cytochrome c oxidase assembly factors SCO1 and SCO2 have regulatory roles in the maintenance of cellular copper homeostasis. Cell Metab (2007) 1.38